Zeki Karasu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4777256/publications.pdf

Version: 2024-02-01

76 papers

1,318 citations

331670 21 h-index 395702 33 g-index

78 all docs 78 docs citations

times ranked

78

1665 citing authors

#	Article	IF	CITATIONS
1	Predictive value of FibroScan in detecting liver fibrosis in HBeAg negative patients with chronic hepatitis B whose HBV DNA 2000-20000 IU/ml with ALT 1-2 times the upper limit of normal and those with HBV DNA >20000 IU/ml and normal ALT. İstanbul Kuzey Klinikleri, 2021, 8, 568-574.	0.3	1
2	Real-world efficacy and safety of Ledipasvir + Sofosbuvir and Om-bitasvir/Paritaprevir/Ritonavir $\hat{A}\pm$ Dasabuvir combination therapies for chronic hepatitis C: A Turkish experience. Turkish Journal of Gastroenterology, 2021, 31, 883-893.	1.1	1
3	Steatotic and Steatohepatitic Hepatocellular Carcinomas. American Journal of Surgical Pathology, 2021, 45, 1252-1263.	3.7	7
4	Recommendations for Hepatitis B Immunoglobulin and Antiviral Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation., 2021, 32, 712-719.		6
5	Standardized versus nonstandardized pharmacologic treatment for hepatorenal syndrome. European Journal of Gastroenterology and Hepatology, 2021, 33, 1334-1335.	1.6	o
6	Infections developing in patients undergoing liver transplantation: Recipients of living donors may be more prone to bacterial/fungal infections. Turkish Journal of Gastroenterology, 2021, 31, 894-901.	1.1	O
7	Prospective randomized single-blind study of post-operative bleeding after minor oral surgery in patients with cirrhosis. Turkish Journal of Gastroenterology, 2019, 30, 171-176.	1.1	17
8	Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a realâ€world chronic hepatitis C patients cohort. Journal of Viral Hepatitis, 2019, 26, 666-674.	2.0	6
9	Paritaprevir, ritonavir, ombitasvir, and dasabuvir treatment in renal transplant patients with hepatitis C virus infection. Turkish Journal of Gastroenterology, 2019, 30, 695-701.	1.1	6
10	Changing patterns of upper gastrointestinal bleeding over 23 years in Turkey. Turkish Journal of Gastroenterology, 2019, 30, 877-882.	1.1	2
11	The Efficacy of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir with or without Ribavirin in Patients with Hepatitis C Undergoing Chronic Haemodialysis: A Single Center Experience. Viral Hepatitis Journal, 2019, 25, 109-112.	0.1	1
12	Increased Peripheral Platelet Count is Unrelated to Decreased Liver Fibrosis Score Following lamivudine Treatment of Patients with Chronic Hepatitis B. , 2018, 08, .		0
13	Results of 1001 liver transplantations in 23 years: Ege University experience. Turkish Journal of Gastroenterology, 2018, 29, 664-668.	1.1	6
14	Turkey 2017 Clinical Practice Guidelines on recommendations for screning diagnosing and managing hepatitis C virus. Turkish Journal of Gastroenterology, 2017, 28, 90-93.	1.1	2
15	Hepatitis B virus infection and reactivation in two patients with anti-HBs following etanercept therapy and alemtuzumab and rituximab therapies: Case presentation. Journal of Clinical Virology, 2016, 82, S69-S70.	3.1	O
16	Magnetic compression anastomosis for patients with a disconnected bile duct after living-donor related liver transplantation: a pilot study. Endoscopy, 2016, 48, 652-656.	1.8	22
17	Tu1569 Magnetic Compression Anastomosis for Patients With a Disconnected Bile Duct After Living Donor Related Liver Transplantation: A Pilot Study. Gastrointestinal Endoscopy, 2016, 83, AB610-AB611.	1.0	О
18	The development of dry eye disease during tenofovir and entecavir therapy in a patient with chronic hepatitis B. Turkish Journal of Gastroenterology, 2016, 27, 474-474.	1.1	1

#	Article	IF	CITATIONS
19	Hepatitis B immune globulin and HBV-related liver transplantation. Marmara Medical Journal, 2016, 29, 38.	0.8	0
20	Seroprevalence of hepatitis A,B, and C viruses in Turkish alcoholic cirrhotics and the impact of hepatitis B on clinical profile. Journal of Infection in Developing Countries, 2015, 9, 254-258.	1.2	6
21	Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clinical Microbiology and Infection, 2015, 21, 1020-1026.	6.0	156
22	Telbivudine in liver transplant recipients: Renal protection does not overcome the risk of polyneuropathy and myopathy. Liver Transplantation, 2015, 21, 1066-1075.	2.4	9
23	Sleep disorders in cirrhotics; How can we detect?. Liver International, 2014, 34, 1192-1197.	3.9	17
24	Diurnal changes of critical flicker frequency in patients with liver cirrhosis and their relationship with sleep disturbances. Digestive and Liver Disease, 2014, 46, 1111-1115.	0.9	8
25	Frontal Skull Metastasis Extending Through the Scalp. Transplantation, 2013, 95, e15-e16.	1.0	4
26	The Association Between Skin Findings and Transplantation Period in Liver Transplant Recipients. Turk Dermatoloji Dergisi, 2013, 7, 72-75.	0.1	1
27	Ornidazole-induced autoimmune hepatitis. Turkish Journal of Gastroenterology, 2011, 22, 494-499.	1.1	14
28	Macrophage migration inhibitory factor expression and MIF gene â^173 G/C polymorphism in nonalcoholic fatty liver disease. European Journal of Gastroenterology and Hepatology, 2010, 22, 192-198.	1.6	24
29	Expression of matrix metalloproteinase-9 in predicting prognosis of hepatocellular carcinoma after liver transplantation. Liver Transplantation, 2010, 16, 621-630.	2.4	62
30	A Pilot Study: Longer Duration of Posttransplant Hepatitis C Virus Therapy May Increase the Sustained Response Rate. Transplantation Proceedings, 2009, 41, 3806-3809.	0.6	1
31	Incidence and diagnosis of active toxoplasma infection among liver transplant recipients in Western Turkey. Liver Transplantation, 2008, 14, 1526-1532.	2.4	18
32	Association of TNF- \hat{l} ± \hat{a} °308 polymorphism with the outcome of hepatitis B virus infection in Turkey. Infection, Genetics and Evolution, 2008, 8, 20-25.	2.3	31
33	Safety, tolerability, and efficacy of pegylatedâ€interferon alfaâ€2a plus ribavirin in HCVâ€related decompensated cirrhotics. Alimentary Pharmacology and Therapeutics, 2008, 27, 1081-1085.	3.7	48
34	Reabsorption of ascites and the factors that affect this process in cirrhosis. Translational Research, 2008, 152, 157-164.	5.0	8
35	Association Between Hepatitis B and Hepatocellular Carcinoma Recurrence in Patients Undergoing Liver Transplantation. Transplantation Proceedings, 2008, 40, 1511-1517.	0.6	25
36	Hepatitis B immune globulin and HBV-related liver transplantation. Expert Opinion on Biological Therapy, 2008, 8, 1815-1822.	3.1	4

#	Article	IF	Citations
37	Live Donor Liver Transplantation for Acute Liver Failure. Transplantation, 2007, 84, 475-479.	1.0	34
38	Living Donor Liver Transplantation From Hepatitis B Core Antibody Positive Donors. Transplantation Proceedings, 2007, 39, 1488-1490.	0.6	20
39	Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 2130-2134.	2.8	43
40	Living donor liver transplantation for hepatitis B cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 2124-2129.	2.8	10
41	Liver Fibrosis Is Associated with Decreased Peripheral Platelet Count in Patients with Chronic Hepatitis B and C. Digestive Diseases and Sciences, 2007, 52, 1535-1539.	2.3	56
42	Liver Biopsy: Is the Pain for Real or is it Only the Fear of it?. Digestive Diseases and Sciences, 2007, 52, 579-581.	2.3	22
43	Adefovir Dipivoxil Alone or in Combination with Lamivudine for Three Months in Patients with Lamivudine Resistant Compensated Chronic Hepatitis B. Digestive Diseases and Sciences, 2007, 52, 3444-3447.	2.3	19
44	Fulminant Budd–Chiari syndrome associated with polycythemia rubra vera and factor V Leiden mutation. European Journal of Internal Medicine, 2006, 17, 66-67.	2.2	7
45	The Prevention of Bone Fractures After Liver Transplantation: Experience With Alendronate Treatment. Transplantation Proceedings, 2006, 38, 1448-1452.	0.6	28
46	The Incidence and Management of Acute and Chronic Rejection After Living Donor Liver Transplantation. Transplantation Proceedings, 2006, 38, 1435-1437.	0.6	17
47	Hyperhomocysteinaemia and factor V Leiden mutation are associated with Budd???Chiari syndrome. European Journal of Gastroenterology and Hepatology, 2006, 18, 917-920.	1.6	10
48	Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation. Osteoporosis International, 2006, 17, 942-949.	3.1	42
49	Successful liver transplantation for giant cell hepatitis and Coombs-positive hemolytic anemia: A case report. Pediatric Transplantation, 2005, 9, 630-633.	1.0	12
50	HBV vaccination in liver transplant recipients: not an effective strategy in the prophylaxis of HBV recurrence. Journal of Viral Hepatitis, 2005, 12, 212-215.	2.0	33
51	Successful Treatment of Liver Transplant-Associated Kaposi's Sarcoma With Long-Term Vincristine. Transplantation Proceedings, 2005, 37, 2188-2189.	0.6	6
52	Liver Failure in Transplanted Liver Due to Amanita Falloides. Transplantation Proceedings, 2005, 37, 2224-2226.	0.6	12
53	Meralgia Paresthetica After Liver Transplantation: A Case Report. Transplantation Proceedings, 2005, 37, 4424-4425.	0.6	6
54	Impact of pretransplant MELD score on posttransplant outcome in living donor liver transplantation. Transplantation Proceedings, 2004, 36, 1442-1444.	0.6	25

#	Article	IF	Citations
55	Rituximab therapy for life-threatining immune hemolytic anemia in a liver tranplant recipient: a case report. Transplantation Proceedings, 2004, 36, 1492-1493.	0.6	8
56	Adefovir treatment in posttransplant hepatitis B virus infection resistant to lamivudine plus hepatitis B virus immunoglobulin. Transplantation Proceedings, 2004, 36, 2768-2770.	0.6	8
57	Variations of hepatic veins: Helical computerized tomography experience in 100 consecutive living liver donors with emphasis on right lobe. Transplantation Proceedings, 2004, 36, 2727-2732.	0.6	32
58	Cytokine gene polymorphism and early graft rejection in liver transplant recipients. Transplantation Proceedings, 2004, 36, 2791-2795.	0.6	15
59	Recipient-Derived Hepatocytes in Sex-Mismatched Liver Allografts after Liver Transplantation: Early versus Late Transplant Biopsies. Transplantation, 2004, 78, 1647-1652.	1.0	29
60	Low-dose hepatitis B immune globulin and higher-dose lamivudine combination to prevent hepatitis B virus recurrence after liver transplantation. Antiviral Therapy, 2004, 9, 921-7.	1.0	11
61	Low-Dose Hepatitis B Immune Globulin and Higher-Dose Lamivudine Combination to Prevent Hepatitis B Virus Recurrence after Liver Transplantation. Antiviral Therapy, 2004, 9, 921-927.	1.0	33
62	Biliary reconstructions and complications encountered in 50 consecutive right-lobe living donor liver transplantations. Liver Transplantation, 2003, 9, 575-580.	2.4	72
63	Liver transplantation in a patient with Budd-Chiari syndrome secondary to factor V Leiden mutation. Transplantation Proceedings, 2003, 35, 3008-3010.	0.6	13
64	Hepatocellular carcinoma in liver transplant era: a clinicopathologic analysis. Transplantation Proceedings, 2003, 35, 2986-2990.	0.6	25
65	Hemophagocytic syndrome after living-related liver transplantation. Transplantation Proceedings, 2003, 35, 1482-1484.	0.6	16
66	Development of hepatocellular carcinoma in hepatitis B virus- and hepatitis C virus-related cirrhosis. Journal of Hepatology, 2002, 36, 76.	3.7	0
67	Sustained response to the interferon therapy in HBeAg(+) chronic hepatitis B is not sustained. Journal of Hepatology, 2002, 36, 96.	3.7	0
68	Comparison of peripheral blood lymphocyte subtypes in renal transplant patients with or without hepatitis C infection. Journal of Hepatology, 2002, 36, 114.	3.7	0
69	Biliary complications following adult-to-adult living donor liver transplantation. Journal of Hepatology, 2002, 36, 189.	3.7	0
70	Mycobacterium tuberculosis infection and laboratory diagnosis in solid-organ transplant recipients. Clinical Transplantation, 2002, 16, 257-261.	1.6	43
71	New frontiers: adult to adult living donor liver transplantation, single center experience from turkey. Transplantation Proceedings, 2001, 33, 3458-3460.	0.6	5
72	Nitroimidazole-induced chronic hepatitis. European Journal of Gastroenterology and Hepatology, 2001, 13, 963-966.	1.6	12

ZEKI KARASU

#	Article	IF	CITATION
73	Severe toxic hepatitis associated with amoxycillin and clavulanic acid. Journal of Clinical Pharmacy and Therapeutics, 2001, 26, 225-229.	1.5	10
74	Effect of transjugular intrahepatic portosystemic shunt on thrombocytopenia associated with cirrhosis. Digestive Diseases and Sciences, 2000, 45, 1971-1976.	2.3	39
75	Spontaneous bacterial peritonitis and refractory ascites. American Journal of Gastroenterology, 2000, 95, 3686-3687.	0.4	O
76	Colorectal Adenomateous Polyps and Helicobacter pylori Infection. American Journal of Gastroenterology, 1999, 94, 1121-1122.	0.4	22